A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: Findings from a population-based, case-control study (the ProtecT study)

International Journal of Molecular Epidemiology and Genetics

Volumn 1, Issue 3, 2010, Pages 175-183

  Murad, Ali S ^a   Smith, George Davey ^a   Lewis, Sarah J ^a   Cox, Angela ^b   Donovan, Jenny L ^a   Neal, David E ^c   Hamdy, Freddie C ^d   Martin, Richard M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Case control study; Diabetes; GCK; Glucokinase; Insulin; Prostate cancer; Prostate specific antigen; rs1799884; Single nucleotide polymorphisms

Indexed keywords

GLUCOKINASE; GLUCOSE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

EID: 77955683628     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, Persson I. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2/5:307-314.
2. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998;9/1:3-9.
3. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and Risk of Prostate Cancer in a Prospective Cohort of US Men. American Journal of Epidemiology 2005;161/2:147-152.
4. Tavani A, Gallus S, Bosetti C, Tzonou A, Lagiou P, Negri E, Trichopoulos D, La Vecchia C. Diabetes and the risk of prostate cancer. Eur J Cancer Prev 2002;11/2:125.
5. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA. Association of Diabetes With Prostate Cancer Risk in the Multiethnic Cohort. Am J Epidemiol 2009;169/8:937-945.
6. DeFronzo RA. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15/3:318-368.
7. Polychronakos C, Janthly U, Lehoux JC, Koutsilieris M. Mitogenic effects of insulin-like growth factors on PA-III rat prostate carcinoma cells: characterization of the receptors involved. Prostate 1991;19:313-321.
8. Hsing AW, Chua S, Jr., Gao YT, Gentzschein E, Chang L, Deng J, Stanczyk FZ. Prostate Cancer Risk and Serum Levels of Insulin and Leptin: a Population-Based Study. J Natl Cancer Inst 2001;93/10:783-789.
9. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG, DepartmentofUrology V, Bronx NY. Increased Serum Insulin Associated With Increased Risk of Prostate Cancer Recurrence.Prostate 2002;50:1-3.
10. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Br J Cancer 2002;87/7:726-728.
11. Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005;41/18:2887-2895.
12. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007;132/6:2208-2225.
13. Ando S, Rubens R, Rottiers R. Androgen plasma levels in male diabetics. J Endocrinol Invest 1984;7/1:21.
14. Barrett-Connor E, Khaw KT, Yen SSC. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol 1990;132/5:895-901.
15. Frayling T, Colhoun H, Florez J. A genetic link between type 2 diabetes and prostate cancer. Diabetologia 2008;51/10:1757-1760.
16. Velicer CM, Dublin S, White E. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 2006;10/1:46-51.
17. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Blondal T, Stacey SN, Helgason A, Gunnarsdottir S, Olafsdottir A, Kristinsson KT, Birgisdottir B, Ghosh S, Thorlacius S, Magnusdottir D, Stefansdottir G, Kristjansson K, Bagger Y, Wilensky RL, Reilly MP, Morris AD, Kimber CH, Adeyemo A, Chen Y, Zhou J, So WY, Tong PCY, Ng MCY, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Tres A, Fuertes F, Ruiz-Echarri M, Asin L, Saez B, van Boven E, Klaver S, Swinkels DW, Aben KK, Graif T, Cashy J, Suarez BK, van Vierssen Trip O, Frigge ML, Ober C, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Palmer CNA, Rotimi C, Chan JCN, Pedersen O, Sigurdsson G, Benediktsson R, Jonsson E, Einarsson GV, Mayordomo JI, Catalona WJ, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007;39/8:977-983.
18. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32/1:1-22.
19. Sandhu M, Debenham S, Barroso I, Loos R. Mendelian randomisation studies of type 2 diabetes: future prospects. Diabetologia 2008;51/2:211-213.
20. Holmkvist J, Almgren P, Lyssenko V, Lindgren CM, Eriksson KF, Isomaa B, Tuomi T, Nilsson P, Groop L. Common Variants in Maturity-Onset Diabetes of the Young Genes and Future Risk of Type 2 Diabetes. Diabetes 2008;57/6:1738-1744.
21. Weedon MN, Clark VJ, Qian Y, Ben-Shlomo Y, Timpson N, Ebrahim S, Lawlor DA, Pembrey ME, Ring S, Wilkin TJ, Voss LD, Jeffery AN, Metcalf B, Ferrucci L, Corsi AM, Murray A, Melzer D, Knight B, Shields B, Smith GD, Hattersley AT, Di Rienzo A, Frayling TM. A Common Haplotype of the Glucokinase Gene Alters Fasting Glucose and Birth Weight: Association in Six Studies and Population-Genetics Analyses. Am J Hum Genet 2006;79/6:991-1001.
22. Tam CHT, Ma RCW, So WY, Wang Y, Lam VKL, Germer S, Martin M, Chan JCN, Ng MCY. Interaction Effect of Genetic Polymorphisms in Glucokinase (GCK) and Glucokinase Regulatory Protein (GCKR) on Metabolic Traits in Healthy Chinese Adults and Adolescents. Diabetes 2009;58/3:765-769.
23. Webster R, Warrington N, Weedon M, Hattersley A, McCaskie P, Beilby J, Palmer L, Frayling T. The association of common genetic variants in the APOA5, LPL and GCK genes with longitudinal changes in metabolic and cardiovascular traits. Diabetologia 2009;52/1:106-114.
24. Winckler W, Weedon MN, Graham RR, McCarroll SA, Purcell S, Almgren P, Tuomi T, Gaudet D, BostrÖm KB, Walker M, Hitman G, Hattersley AT, McCarthy MI, Ardlie KG, Hirschhorn JN, Daly MJ, Frayling TM, Groop L, Altshuler D. Evaluation of Common Variants in the Six Known Maturity- Onset Diabetes of the Young (MODY) Genes for Association With Type 2 Diabetes. Diabetes 2007;56/3:685-693.
25. Vaxillaire M, Veslot J, Dina C, Proenca C, Cauchi S, Charpentier G, Tichet J, Fumeron F, Marre M, Meyre D, Balkau B, Froguel P, for the DESIR Study Group. Impact of Common Type 2 Diabetes Risk Polymorphisms in the DESIR Prospective Study. Diabetes 2008;57/1:244-254.
26. Stone LM, Kahn SE, Fujimoto WY, Deeb SS, Porte Jr D. A variation at position-30 of the betacell glucokinase gene promoter is associated with reduced beta-cell function in middle-aged Japanese-American men. Diabetes 1996;45/4:422-428.
27. Rose CS, Ek J, Urhammer SA, Glumer C, Borch-Johnsen K, Jorgensen T, Pedersen O, Hansen T. A -30G>A Polymorphism of the {beta}-Cell-Specific Glucokinase Promoter Associates With Hyperglycemia in the General Population of Whites. Diabetes 2005;54/10:3026-3031.
28. Rissanen J, Saarinen L, Heikkinen S, Kekalainen P, Mykkanen L, Kuusisto J, Deeb SS, Laakso M. Glucokinase gene islet promoter region variant (G-->A) at nucleotide -30 is not associated with reduced insulin secretion in Finns. Diabetes Care 1998;21/7:1194-1197.
29. Matsuda M, Mari A, DeFronzo RA. World Health Organization & International Diabetes Federation.Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: WHO Press: 2006.
30. Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, Jewell D, Powell P, Gillatt D, Dedman D. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003;7/14:1-88.
31. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39/5:645-649.
32. Avery KNL, Blazeby JM, Lane JA, Neal DE, Hamdy FC, Donovan JL. Decision-Making about PSA Testing and Prostate Biopsies: A Qualitative Study Embedded in a Primary Care Randomised Trial. Eur Urol 2008;53/6:1186-1193.
33. Zuccolo L, Harris R, Gunnell D, Oliver S, Lane JA, Davis M, Donovan J, Neal D, Hamdy F, Beynon R. Height and Prostate Cancer Risk: A Large Nested Case-Control Study (ProtecT) and Meta-analysis. Cancer Epidemiol Biomarkers Prev 2008;17/9:2325-2336.
34. Stata Press. Stata Reference Manual Release 10. College Station, TX: Stata Press: 2007.
35. Schumacher FR, Feigelson HS, Cox DG, Haiman CA, Albanes D, Buring J, Calle EE, Chanock SJ, Colditz GA, Diver WR. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res 2007;67/7:2951.
36. Kristal AR, Stanford JL. Cruciferous Vegetables and Prostate Cancer Risk Confounding by PSA Screening. Cancer Epidemiol Biomarkers Prev 2004;13/7:1265.
37. Giovannucci E, Liu Y, Platz E, Stampfer M, Willett W. Risk factors for prostate cancer incidence and progression in the health professionals follow- up study. Int J Cancer 2007;121/7:1571-1578.
38. Stanford JL, McDonnell SK, Friedrichsen DM, Carlson EE, Kolb S, Deutsch K, Janer M, Hood L, Ostrander EA, Schaid DJ. Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. Prostate 2006;66/3.
39. Ostrander EA, Kwon EM, Stanford JL. Genetic susceptibility to aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15/10:1761.
40. Schaid DJ. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet 2006;120/4:471-485.
41. Paiss T, Worner S, Kurtz F, Haeussler J, Hautmann RE, Gschwend JE, Herkommer K, Vogel W. Linkage of aggressive prostate cancer to chromosome 7q31-33 in German prostate cancer families. Eur J Hum Genet 2003;11/1:17-22.
42. Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G, Sun J, Chang BL, Marovich L, Wiley KE, Balter K, Stattin P, Adami HO, Gielzak M, Yan G, Sauvageot J, Liu W, Kim JW, Bleecker ER, Meyers DA, Trock BJ, Partin AW, Walsh PC, Isaacs WB, Gronberg H, Xu J, Carpten JD. Two Genome-wide Association Studies of Aggressive Prostate Cancer Implicate Putative Prostate Tumor Suppressor Gene DAB2IP. J Natl Cancer Inst 2007;99/24:1836-1844.
43. Sun J, Zheng SL, Wiklund F, Isaacs SD, Li G, Wiley KE, Kim ST, Zhu Y, Zhang Z, Hsu FC. Sequence Variants at 22q13 Are Associated with Prostate Cancer Risk. Cancer Res 2009;69/1:10.
44. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen. N Engl J Med 2003;349/4:335-342.
45. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA, Jr. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level <=4.0 ng per Milliliter. N Engl J Med 2004;350/22:2239-2246.
46. Eeles RA, Kote-Jarai Z, Giles GG, Olama AAA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40/3:316-321.
47. Levin AM, Machiela MJ, Zuhlke KA, Ray AM, Cooney KA, Douglas JA. Chromosome 17q12 Variants Contribute to Risk of Early-Onset Prostate Cancer. Cancer Res 2008;68/16:6492-6495.
48. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Balter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Gronberg H. Cumulative Association of Five Genetic Variants with Prostate Cancer. N Engl J Med 2008;358/9:910-919.
49. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008;40/3:310-315.
50. Rockwood K, Awalt E, MacKnight C, McDowell I. Incidence and outcomes of diabetes mellitus in elderly people: report from the Canadian Study of Health and Aging. CMAJ 2000;162/6:769-772.
51. Martin LM, Leff M, Calonge N, Garrett C, Nelson DE. Validation of self-reported chronic conditions and health services in a managed care population. Am J Prev Med 2000;18/3:215-218.
52. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57/10:1096-1103.